Rotavirus vaccines: An update

Current Opinion in Pediatrics

Volumn 17, Issue 1, 2005, Pages 88-92

  Dennehy, Penelope H ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Rotavirus; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

CLINICAL TRIAL; DEHYDRATION; DIARRHEA; GASTROENTERITIS; HUMAN; IMMUNIZATION; INTUSSUSCEPTION; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; ROTAVIRUS; SEROTYPE; VACCINATION; VIRUS INFECTION;

CHILD, PRESCHOOL; DIARRHEA; HUMANS; INFANT; INTUSSUSCEPTION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 12744277954     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000147907.30720.04     Document Type: Review

References (43)

1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-572. An excellent review of the global burden of rotavirus disease.
2. Miller MA, McCann L: Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000; 9:19-35.
3. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174(suppl 1):S5-S11.
4. Parashar UD, Chung MA, Holman RC, et al. Use of state hospital discharge data to assess the morbidity from rotavirus diarrhea and to monitor the impact of a rotavirus immunization program: a pilot study in Connecticut. Pediatrics 1999; 104:489-494.
5. Hoshino Y, Kapikian AZ: Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr 2000; 18:5-14.
6. Gentsch JR, Woods PA, Ramachandran M, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996; 174(suppl 1):S30-S36.
7. Steele AD, Ivanoff B: Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003; 21:361-367.
8. Bishop RF, Barnes GL, Cipriani E, et al. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983; 309:72-76.
9. Bhan MK, Lew JF, Sazawal S, et al. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J Infect Dis 1993; 168:282-287.
10. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-1028.
11. Ward RL: Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model. Viral Immunol 2003; 16:17-24. This paper describes a mouse model that provides useful insights on the immunological responses to rotavirus infection and control of disease.
12. Hoshino Y, Kapikian AZ: Rotavirus vaccine development for the prevention of severe diarrhea in infants and young children. Trends Microbiol 1994; 2:242-249.
13. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999; 354:287-290.
14. Barnes GL, Lund JS, Mitchell SV, et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002; 20:2950-2956.
15. Vesikari T, Isolauri E, D'Hondt E, et al.: Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1:977-981.
16. Perez-Schael I, Garcia D, Gonzalez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 1990; 30:219-229.
17. Kapikian AZ, Hoshino Y, Chanock RM, et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996; 174(suppl 1):S65-S72.
18. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7-13.
19. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-638.
20. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-1187. [published erratum appears in N Engl J Med 1998, 338:1002.]
21. Joensuu J, Koskenniemi E, Pang XL, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-1209.
22. Centers for Disease Control and Prevention: Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48:1-20.
23. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174(suppl 1):S73-S80.
24. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004; 144:184-190. The proof of efficacy study for this human-bovine reassortant vaccine.
25. Vesikari T, Ruuska T, Koivu HP, et al. Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants. Pediatr Infect Dis J 1991; 10:912-917.
26. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-387.
27. Bernstein DI, Sack DA, Reisinger K, et al. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002; 186:1487-1489.
28. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-572.
29. Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003; 187:1301-1308. An editorial that expresses concern about the interpretation of the epidemiological data that supported the ACIP decision to withdraw RRV-TV.
30. Murphy TV, Smith PJ, Gargiullo PM, et al. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. J Infect Dis 2003; 187:1309-1313. A discussion of the data that led to the ACIP's decision to withdraw the recommendation for use of RRV-TV.
31. Rhodes P, DeStefano F, Chen R, et al. Long-term risk of intussusception following Rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV). Abstract of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois: 2003; Abstract G-2052.
32. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004; 363:1547-1550. An editorial reviewing the positive and negative effects of the withdrawal of RRV-TV on the development of rotavirus vaccines.
33. Robinson CG, Hernanz-Schulman M, Zhu Y, et al. Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? J Infect Dis 2004; 189:1382-1387. An interesting study of the anatomic changes seen in the gastrointestinal tract with natural rotavirus infection that support the biological plausibility of the association of rotavirus infection with intussusception.
34. Mohan KV, Kulkarni S, Glass RI, et al. A human vaccine strain of lamb rotavirus (Chinese) NSP4 gene: complete nucleotide sequence and phylogenetic analyses. Virus Genes 2003; 26:185-192.
35. Clark HF, Burke CJ, Volkin DB, et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003; 22:914-920.
36. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 2002; Abstract G-1220.
37. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2836-2842. This Phase II study of Rotarix, the vaccine candidate derived from the attenuated human 89-12 strain, shows that this vaccine is safe and immunogenic, paving the way for Phase III studies in young infants.
38. Hoshino Y, Jones RW, Ross J, et al. Construction and characterization of rhesus monkey rotavirus (MMU18006)- or bovine rotavirus (UK)-based serotype G5, G8, G9 or G10 single VP7 gene substitution reassortant candidate vaccines. Vaccine 2003; 21:3003-3010.
39. Eichelberger MC, Sperber E, Wagner M, et al. Clinical evaluation of a single oral dose of human-bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS-1 x UK) (P1A[8],G2). J Med Virol 2002; 66:407-416.
40. Clements-Mann ML, Dudas R, Hoshino Y, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001; 19:4676-4684.
41. Chen SC, Fynan EF, Robinson HL, et al. Protective immunity induced by rotavirus DNA vaccines. Vaccine 1997; 15:899-902.
42. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, et al. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003; 21:3885-3900.
43. Gonzalez AM, Nguyen TV, Azevedo MS, et al. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM. Clin Exp Immunol 2004; 135:361-372.